List of Excipients in Branded Drug CEFEPIME HYDROCHLORIDE AND DEXTROSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CEFEPIME HYDROCHLORIDE AND DEXTROSE	cefepime hydrochloride	0264-3193	DEXTROSE MONOHYDRATE
B Braun Medical Inc	CEFEPIME HYDROCHLORIDE AND DEXTROSE	cefepime hydrochloride	0264-3193	WATER

Cefepime Hydrochloride and Dextrose Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Cefepime hydrochloride and dextrose injection is a mature hospital anti-infective product in which commercial value comes from formulation reliability, ready-to-administer presentation, supply continuity, and workflow savings rather than new-molecule exclusivity. The strongest opportunities are premixed intravenous bags, flexible container systems, extended stability, pediatric and renal-dose presentations, elastomeric infusion devices, and contract manufacturing for hospitals and public-sector buyers.

What is cefepime hydrochloride and dextrose injection?

Cefepime hydrochloride and dextrose injection is an intravenous formulation of cefepime, a fourth-generation cephalosporin antibacterial, in a dextrose solution. Dextrose commonly functions as the vehicle and contributes osmotic content. It is not the product’s antimicrobial active ingredient.

Cefepime is used for serious bacterial infections, including pneumonia, urinary tract infections, skin and skin-structure infections, intra-abdominal infections when combined with metronidazole, and febrile neutropenia. Its activity includes many Gram-negative organisms, including Pseudomonas aeruginosa, while retaining activity against selected Gram-positive pathogens.[1]

The formulation is generally positioned for hospital and institutional use because intravenous administration requires trained personnel, sterile handling, and monitoring. The principal commercial alternatives are:

• Cefepime sterile powder for reconstitution.
• Cefepime premixed in dextrose injection.
• Other antipseudomonal beta-lactams, including piperacillin/tazobactam, ceftazidime, meropenem, and aztreonam.
• Outpatient parenteral antimicrobial therapy products delivered through elastomeric pumps or other infusion systems.

Which excipients are used in cefepime hydrochloride and dextrose products?

The central excipient system is a dextrose-containing aqueous vehicle. Commercial products may also contain pH-adjusting agents, depending on the manufacturer and presentation. The label for a specific product controls the exact qualitative and quantitative composition.

Formulation element	Commercial function	Key development issue
Cefepime hydrochloride	Active pharmaceutical ingredient	Potency, degradation, impurity control, antimicrobial activity
Dextrose	Isotonic or near-isotonic vehicle and carbohydrate source	Concentration, osmolarity, diabetic-patient considerations, stability
Water for injection	Solvent	Sterility, endotoxin, container compatibility
pH adjustment system	Maintains product stability and tolerability	Local pH, degradation rate, precipitation risk
Primary container	Protects sterile solution	Extractables, leachables, oxygen and moisture transmission
Overwrap or secondary package	Protects against light and moisture	Shelf-life and transport robustness

Dextrose concentration should be selected with the intended patient population and administration setting in mind. A dextrose vehicle can be operationally convenient, but it may be less attractive for patients requiring tight glucose management or for institutions standardizing around saline-based infusions.

A formulation program should not treat dextrose as an interchangeable commodity. Its concentration affects osmolality, infusion tolerability, labeling, and the suitability of the product for different clinical protocols.

What formulation patents protect cefepime hydrochloride and dextrose products?

The original cefepime compound and early pharmaceutical rights are mature and do not provide a practical basis for current U.S. product differentiation. Cefepime was commercialized decades ago, and generic competition has been established for both powder and ready-to-use intravenous products.

The commercially relevant intellectual property questions now concern formulation and delivery execution:

1. Ready-to-use sterile solution patents. These may cover solution composition, pH control, concentration ranges, or stability profiles.
2. Container patents. Flexible polyolefin bags, multilayer films, ports, seals, and oxygen-barrier structures can be protected separately from the drug formulation.
3. Infusion-device patents. Elastomeric pumps, dual-chamber systems, and integrated administration sets may have independent rights.
4. Manufacturing patents. Sterile filtration, aseptic filling, terminal sterilization, mixing order, and control of degradation products may be protectable.
5. Method-of-use patents. New dosing schedules or disease-specific uses may be relevant in principle, but mature cefepime products generally face limited practical protection from broad method-of-use claims.
6. Trade secrets. Validated hold times, filling parameters, container closure controls, and impurity-management procedures may be more commercially valuable than a narrow patent.

For a new entrant, the relevant freedom-to-operate review should cover the finished product, container system, closure, infusion device, manufacturing process, and proposed labeling. A search limited to cefepime composition patents would not capture the principal commercial risks.

When does cefepime lose exclusivity?

Cefepime’s original small-molecule exclusivity has expired. The U.S. market is therefore governed primarily by abbreviated new drug application approvals, product-quality requirements, supply capacity, and institutional contracting.

The product has no biosimilar pathway because cefepime is a chemically synthesized small molecule rather than a biologic. FDA approval generally proceeds through the abbreviated new drug application pathway when the proposed product demonstrates pharmaceutical equivalence and bioequivalence or meets the applicable requirements for injectable products.[2]

Exclusivity category	Current commercial relevance
Original compound patent	Expired or commercially obsolete
New chemical entity exclusivity	Expired
Pediatric exclusivity	No material protection for a new entrant absent a qualifying regulatory grant
Orphan-drug exclusivity	Generally not applicable to the broad cefepime product
Formulation exclusivity	Depends on product-specific FDA approval and patent filings
Device exclusivity	May apply to a proprietary infusion system, not to cefepime itself
Regulatory exclusivity for a new generic	Usually limited and product-specific

The practical entry barrier is not molecule exclusivity. It is the ability to produce a sterile, stable, specification-compliant solution at scale and maintain supply during hospital demand surges.

What is the Orange Book status of cefepime and dextrose injection?

Orange Book analysis must be performed at the specific product and application level. FDA’s Orange Book identifies approved drug products and relevant patent or exclusivity information, but discontinued or withdrawn products can create confusion between historical reference products and currently marketed products.[3]

For cefepime and dextrose injection, the relevant review should distinguish:

• The reference listed drug.
• Currently approved abbreviated new drug applications.
• Strength and container-size differences.
• Premixed solution products versus powder products.
• Active, discontinued, and withdrawn product records.
• Any listed patents for the specific reference product.
• Whether a patent certification is required for a proposed ANDA.

Cefepime powder for reconstitution and cefepime premixed solution should not be treated as identical regulatory products. Their pharmaceutical forms, excipient systems, manufacturing controls, and labeling can differ materially.

Which companies are challenging cefepime market exclusivity?

The cefepime market has historically included multiple generic injectable manufacturers and contract manufacturers. Competitive participation can change because of facility status, product discontinuations, shortages, acquisition activity, and government contracting.

The main competitor groups are:

• Large generic injectable companies.
• Hospital-focused sterile manufacturers.
• Contract development and manufacturing organizations.
• Specialty manufacturers supplying premixed bags.
• Firms offering compounded or outsourced hospital products where permitted by applicable law.
• Manufacturers integrating cefepime into elastomeric infusion systems.

A company entering this market would compete against products with established hospital formulary status. FDA approval alone may not secure volume. Buyers typically evaluate price, backorder history, minimum order quantities, expiration dating, package configuration, recall record, and the ability to supply multiple strengths.

What formulation strategy creates the strongest commercial position?

The most defensible formulation strategy combines chemical stability with operational convenience.

Ready-to-use premixed bags

Premixed bags eliminate pharmacy reconstitution and reduce manipulation of injectable antibiotics. The value proposition is strongest in emergency departments, intensive-care units, operating rooms, decentralized pharmacies, and hospitals with limited compounding capacity.

Commercial advantages include:

• Lower preparation labor.
• Fewer reconstitution errors.
• Faster time to administration.
• Lower exposure to needle-stick and compounding risks.
• Easier inventory standardization.
• Compatibility with automated dispensing and barcode workflows.

Extended refrigerated and room-temperature stability

Stability is a major differentiator. A product with a longer refrigerated shelf life, a meaningful room-temperature excursion window, or a validated in-use period can reduce wastage and improve deployment during emergencies.

A development program should evaluate:

• Assay and degradation products.
• Solution color and visible particles.
• pH drift.
• Container closure integrity.
• Oxygen exposure.
• Freeze-thaw stress.
• Light exposure.
• Shipping vibration and temperature excursions.
• Compatibility with common administration sets and pumps.

Claims of extended stability require product-specific supporting data and cannot be inferred from the stability of cefepime powder.

Multiple concentrations and dose presentations

A commercially useful portfolio may include concentrations aligned with common adult and pediatric dosing. Product sizes should reflect actual hospital protocols rather than simply multiplying vial strengths.

High-value configurations may include:

• Standard adult doses.
• Low-volume pediatric presentations.
• Renal-adjustment presentations.
• Premixed bags for emergency use.
• Higher-concentration bags for fluid-restricted patients.
• Unit-of-use formats for automated medication cabinets.

Renal dosing is commercially important because cefepime accumulation can cause serious neurotoxicity when dosing is not adjusted for renal function.[1] Clear strength differentiation and barcode controls can reduce selection errors.

What manufacturing and IP barriers affect cefepime premixed products?

The manufacturing barrier is higher for a ready-to-use sterile solution than for a conventional powder vial.

Key technical risks include:

• Cefepime degradation in aqueous solution.
• Formation and control of degradation impurities.
• pH-dependent instability.
• Interaction with bag films, ports, and tubing.
• Oxygen or light sensitivity.
• Sterile filtration and aseptic-processing risk.
• Container closure integrity over the full shelf life.
• Microbial contamination during filling.
• Product loss from adsorption or precipitation.
• Visual defects that trigger batch rejection.

A powder product transfers more preparation responsibility to the hospital but can offer greater stability. A premixed solution transfers more development and manufacturing responsibility to the sponsor but creates a stronger workflow proposition.

Potential IP positions are strongest when they cover a defined and difficult-to-reproduce combination of cefepime concentration, pH, excipient level, container material, storage condition, and stability outcome. Broad claims directed only to cefepime in dextrose are likely to face validity and design-around pressure in a mature market.

What generic entry risks exist for cefepime hydrochloride and dextrose?

Generic entry risk is high for the active ingredient and basic powder presentations. It is more differentiated for premixed products because sterile solution manufacturing and container compatibility increase the operational burden.

Entry type	Risk level	Reason
Cefepime powder vial	High	Mature active ingredient and established generic pathway
Standard reconstituted cefepime	High	Hospital familiarity and multiple suppliers
Cefepime in dextrose premix	Moderate to high	More complex sterile-solution manufacturing
Extended-stability premix	Moderate	Stability data and container system may differentiate
Elastomeric cefepime product	Moderate	Device, stability, and outpatient-use requirements
Novel dual-chamber presentation	Moderate	Higher device and manufacturing complexity
New broad method of use	Low	Limited practical protection for mature antibacterial

The largest commercial risk is price compression. The largest supply risk is manufacturing concentration. The largest technical risk is failure to maintain potency and impurity specifications throughout the proposed shelf life.

How does cefepime premix compare with competing antipseudomonal antibiotics?

Cefepime premix competes on spectrum, dosing familiarity, compatibility with institutional protocols, and procurement economics.

Product category	Primary commercial advantage	Main limitation
Cefepime premix	Familiar fourth-generation cephalosporin; convenient administration	Renal dosing and neurotoxicity concerns
Piperacillin/tazobactam	Broad coverage including anaerobes	Larger infusion volumes and beta-lactam allergy concerns
Ceftazidime	Strong Gram-negative and antipseudomonal positioning	Weaker Gram-positive coverage
Meropenem	Broad spectrum and severe-infection utility	Higher stewardship restrictions and cost
Aztreonam	Option for selected beta-lactam-allergic patients	Narrower clinical positioning
Cefepime powder	Lower manufacturing complexity	Requires pharmacy preparation

A cefepime premix is most attractive where hospitals value rapid administration and have protocols that already favor cefepime for suspected Gram-negative or Pseudomonas infections.

What licensing deals and partnerships are commercially relevant?

Licensing opportunities are more likely to involve manufacturing and delivery technology than cefepime molecule rights.

Potential partnership structures include:

• Supply agreements with hospital purchasing organizations.
• CDMO arrangements for aseptic filling.
• Co-development of flexible bag or dual-chamber systems.
• Rights to elastomeric infusion devices.
• Regional commercialization licenses.
• Government and public-health supply contracts.
• Portfolio deals covering several sterile anti-infective products.

A cefepime product can strengthen a broader hospital-injectables portfolio by sharing sales channels, packaging infrastructure, quality systems, and distribution arrangements. The commercial case improves when the sponsor can bundle cefepime with other frequently purchased injectable antibiotics.

What is the FDA regulatory status of cefepime premixed injection?

FDA-regulated cefepime products must meet requirements for sterile injectable drugs, including identity, strength, quality, purity, sterility, endotoxin control, container closure integrity, and stability. Depending on the product, approval may proceed through an ANDA or another applicable pathway.

The label must address:

• Indications and usage.
• Dosing by infection and patient population.
• Renal dose adjustment.
• Preparation and administration instructions.
• Compatibility and incompatibility information.
• Storage conditions.
• Warnings for hypersensitivity and neurotoxicity.
• Drug interactions and laboratory effects.
• Disposal and handling requirements.

A ready-to-use product may reduce preparation instructions but cannot eliminate the need for administration-specific labeling. The sponsor must validate the full package, including the bag, ports, overwrap, administration set, and any proposed device.

What is the revenue exposure and commercial opportunity?

Cefepime is a mature, high-volume hospital antibiotic, but unit pricing is generally constrained by generic competition and group purchasing organizations. Revenue growth is more likely to come from share capture and product differentiation than from price increases.

The most attractive commercial segments are:

1. Hospitals seeking ready-to-use sterile bags.
2. Emergency and intensive-care settings where preparation time matters.
3. Pediatric hospitals requiring smaller volumes and clear dose differentiation.
4. Outpatient parenteral antimicrobial therapy providers.
5. Public-sector buyers prioritizing supply reliability.
6. Markets with recurring injectable-antibiotic shortages.
7. International regions where premixed sterile antibiotics remain underdeveloped.

A sponsor should model revenue by units supplied, not by theoretical treatment population. Important assumptions include average contract price, hospital conversion rate, annual units per account, tender duration, manufacturing yield, batch-failure rate, freight costs, and expected competition.

What geographic markets offer the best opportunity?

The United States offers a large institutional market but has aggressive generic pricing and demanding regulatory requirements. Europe and other regulated markets may offer opportunities for premixed products where hospital pharmacy labor costs and centralized procurement favor ready-to-use presentations.

Emerging markets may offer volume but require attention to:

• Local registration requirements.
• Cold-chain and temperature-excursion conditions.
• Tender pricing.
• Local manufacturing or packaging rules.
• Counterfeit protection.
• Hospital storage capabilities.
• Availability of dextrose-based infusion solutions.

A regional strategy should not assume that the U.S. container, concentration, labeling, or shelf-life package transfers directly to another jurisdiction.

How strong is the patent estate for cefepime hydrochloride and dextrose?

The molecule-level patent estate is weak as a current barrier because cefepime is an established generic active ingredient. A defensible estate must be built around product-specific technical features.

IP layer	Relative strength	Commercial value
Cefepime compound claims	Low	Historical only
Broad cefepime-in-dextrose claims	Low to moderate	Vulnerable to design-around
Narrow stability composition claims	Moderate	Useful if technically reproducible
Container and closure claims	Moderate	Can support product differentiation
Device combination claims	Moderate	Relevant to outpatient delivery
Manufacturing process claims	Moderate	Stronger when process is difficult to replicate
Trade secrets and know-how	High operational value	Important for yield and quality consistency
Brand and supply reputation	High commercial value	Critical in hospital contracting

Patent strength should be assessed with claim construction, validity analysis, prosecution history, and design-around testing. In this market, a technically difficult product with reliable supply may be more valuable than a broad but vulnerable patent claim.

Key Takeaways

• Cefepime hydrochloride and dextrose is a mature generic injectable product with limited molecule-level exclusivity.
• Dextrose is a vehicle and formulation variable, not a source of antimicrobial differentiation.
• Ready-to-use bags, extended stability, pediatric presentations, and infusion-device integration offer the clearest commercial opportunities.
• The primary technical risks are aqueous degradation, impurity control, container compatibility, and sterile manufacturing.
• Generic entry risk is high for powder products and somewhat lower for sophisticated premixed or device-enabled presentations.
• Patent value is concentrated in formulation, container, manufacturing, and delivery-system claims.
• Hospital contracting, supply reliability, shortage responsiveness, and workflow savings will determine commercial performance.
• Cefepime has no biosimilar risk because it is a small-molecule antibacterial.
• FDA Orange Book analysis must distinguish reference products, approved generics, dosage forms, and product-specific patent listings.
• A portfolio strategy combining cefepime with other sterile anti-infectives can improve manufacturing utilization and contracting leverage.

FAQs about cefepime hydrochloride and dextrose

Is dextrose in cefepime injection therapeutically active?

No. Dextrose is primarily the injectable vehicle and contributes to solution tonicity. Its concentration can affect osmolarity, labeling, and suitability for patients with glucose-management concerns.

Can cefepime be formulated in normal saline instead of dextrose?

Cefepime products may be formulated or diluted in different compatible solutions, but the approved vehicle and stability profile are product-specific. A saline formulation requires its own development, compatibility, and regulatory support.

What is the main advantage of a cefepime premixed bag?

The main advantage is eliminating pharmacy reconstitution. This can reduce preparation labor, shorten administration time, and lower manipulation-related error risk.

Does cefepime premix require a proprietary container to obtain market protection?

No. A proprietary container is not required, but container technology can support stability, usability, device integration, or patent protection if it provides a defined technical advantage.

Why is renal dosing important in a cefepime commercial strategy?

Cefepime is primarily renally eliminated. Accumulation in patients with impaired renal function can increase neurotoxicity risk, making clear strength selection, labeling, and clinical workflow integration important product attributes.

References

1. Pfizer Inc. (2023). MAXIPIME (cefepime hydrochloride) for injection prescribing information. U.S. Food and Drug Administration/DailyMed.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Drug shortages database. FDA.